Back to search

Article

The Third Dose of the SARS-CoV-2 Vaccine: Why and for Whom?

2022-01-28

Abstract excerpt

The authors of this brief commentary give an update on the results of the last studies on the antibody response to the so-called “booster” administration of the Severe Acute Respiratory Syndrome (SARS)-CoronaVirus (CoV)-2 vaccines, with particular reference to the new “omicron” variant. A brief overview of the immunological response to this infection is also provided, with the advise that a serological test before...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
66b7a034-6806-536d-a85e-83b8981754a7
DOI
10.21467/preprints.373
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
The Third Dose of the SARS-CoV-2 Vaccine: Why and for Whom?DOI 10.21467/preprints.373
Humoral and cellular response induced by a second booster of an inactivated SARS-CoV-2 vaccine in adultsSemantic proximity
Third SARS-CoV-2 Vaccination and Breakthrough Infections Enhance Humoral and Cellular Immunity Against Variants of ConcernSemantic proximity
Four doses of the inactivated SARS-CoV-2 vaccine redistribute humoral immune responses away from the Receptor Binding DomainSemantic proximity
Neutralizing antibodies to Omicron after the fourth SARS-CoV-2 mRNA vaccine dose in immunocompromised patients highlight the need of additional boostersSemantic proximity
Immunogenicity and Safety of Gamma, Omicron BA.4/5 and Bivalent SARS-CoV-2 RBD-based Protein Booster Vaccines in Adults Previously Immunized with Different Vaccine Platforms: a Phase II/III, Randomized, Clinical TrialSemantic proximity
Immunogenicity and safety of inactivated SARS-CoV-2 vaccine (CoronaVac) using two-dose primary protocol in children and adolescents (Immunita-002, Brazil): A phase IV six-month follow upSemantic proximity
Immunogenicity and Safety of COVID-19 Booster Vaccination: A Real-World Clinical Trial to Identify the Best Vaccination StratagySemantic proximity
Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001): A One Year Period Follow Up Phase 4 StudySemantic proximity
A booster dose of an inactivated SARS-CoV-2 vaccine increases neutralizing antibodies and T cells that recognize Delta and Omicron variants of concernSemantic proximity
Neutralizing Activities against the Omicron Variant after a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac VaccinationSemantic proximity
Increased seroprevalence and improved antibody responses following third primary SARS-CoV-2 immunisation: an update from the COV-AD studySemantic proximity
Antibody Titers After a Third Dose of the SARS-CoV-2 BNT162b2 Vaccine in Immunocompromised Adults in Greece: Necessity of a Fourth DoseSemantic proximity
Select a neighboring publication to make it the new centre.